stockrowBelite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) Return on invested capital
Belite Bio, Inc. Sponsored ADR's return on invested capital over the twelve months to 30 June 2026 was −9.55%, up 9.4 percentage points from fiscal 2025 (−18.9%). Over the past ten years it has ranged from −3,719.9% (fiscal 2024) to 0.00% (fiscal 2022); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −18.9% | 3,700.94 |
| FY2024 | −3,719.9% | (2,849.49) |
| FY2023 | −870.4% | (870.38) |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 17.7% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.27% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IONS Ionis Pharmaceuticals, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR | −9.55% |
| ORKA Oruka Therapeutics, Inc. compare | −40.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −184.7% |
| CGON CG Oncology, Inc. compare | −4,111.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)